Bryxta® 300
Brand Name: Bryxta® 300
Composition: Bevacizumab Injection (300 mg/12 mL)
Product Description
Medical Info
Bryxta® 300 (Bevacizumab) is a prescription medicine, manufactured by Zydus Oncosciences, used for the treatment of various types of cancers. It is classified as an angiogenesis inhibitor, which works by targeting and inhibiting the growth of new blood vessels that supply oxygen and nutrients to tumors, thereby potentially slowing their growth. Each pack contains one single-use vial with a concentration of 300 mg/12 mL and a corresponding package insert. Bryxta® 300 is specifically formulated for administration via intravenous infusion under the supe
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
